Excellence in clinical research from A to Z

Scroll down ⇩

About us

AtoZ-CRO GmbH is a full-service clinical research organisation (CRO) located in Overath near Cologne, Germany, with over 30 years of experience in clinical development and clinical study management. As a specialist for Germany, Europe, the US, and India, AtoZ-CRO offers a broad range of professional services and partner solutions for international clinical studies with pharmaceuticals and medical devices.


From its head office located in Overath, Germany, AtoZ-CRO manages and coordinates clinical studies of phase 0 through phase IV for national and international clients. The company forms a team of 35 highly experienced and dedicated industry professionals and medical specialists ensuring high standards in clinical study management. AtoZ-CRO is affiliated with a leading initiator of phase I studies in Warsaw, Poland.


Based on the company’s long-established international experience in clinical trial management and cooperation with high-rated business partners, AtoZ-CRO is proud to offer a broad range of services covering all clinical research needs, in particular for small and mid-sized pharmaceutical, biotech, and medical device companies.

Clinical Studies 

Contact us

Clinical Studies

Clinical Studies Phases 0 – IV

  • Planning of clinical studies
  • Preparation of study protocols
  • Design and implementation of CRFs (case report forms) and eCRFs
  • Processing of applications for ethical votes and permissions (e.g. CTA, IND)
  • Regulatory affairs issues
  • Legal EU representative

Other services

  • Monitoring
  • Post-marketing studies

-  NIS

-  PASS

-  Epidemiology

  • Pharmacovigilance
  • Biometry
  • Medical Writing and Translations

About us

Contact us

Contact us

AtoZ-CRO GmbH

Hauptstr. 77
51491 Overath
Tel: 02206 95 99 0
Fax: 02206 820 63
Email: info@atoz-cro.de
www.atoz-cro.de

Business Development

Alexa Foltin-Mertgen, M.Sc.
Email: a.foltin-mertgen@atoz-cro.de

Back to top ⇧

Go to article: Home | Invest in TechGo to article: In this issueGo to article: Gerteis Company InsightGo to article: GerteisGo to article: ContentsGo to article: DJAGo to article: NewsGo to article: MedelpharmGo to article: Biotech M&A: will the 2018 surge last?Go to article: NSFGo to article: Can the gene and cell therapy revolution scale up?Go to article: Haselmeier GmbH Company InsightGo to article: Haselmeier GmbH Go to article: Gut instinct: how common drugs affect the microbiomeGo to article: HOF Sonderanlagenbau Company InsightGo to article: HOF SonderanlagenbauGo to article: Tracing the story of mumps: a timelineGo to article: Molnar Company InsightGo to article: MolnarGo to article: Inside Swiss pharma: the ideal environment for successGo to article: Is the UK’s drug evaluation system in need of an overhaul?Go to article: Scandinavian Health Ltd. Company InsightGo to article: Scandinavian Health Ltd.Go to article: MoehsGo to article: Could digital tech unlock billions in savings for pharma companies?Go to article: EcocoolGo to article: CRISPR: a seismic shift in gene editingGo to article: Mestra AG (Endress + Hauser)Go to article: EventsGo to article: Pfanstiehl Inc Company InsightGo to article: Pfanstiehl Inc.Go to article: Next issueGo to article: Niconex Medical LtdGo to article: Alpex Pharma SAGo to article: Pall Biotech Company InsightGo to article: Pall BiotechGo to article: AtoZ-CRO GmbHGo to article: WIKA - Disaster preventionGo to article: Bea TechnologiesGo to article: BaxterGo to article: SuezGo to article: Raland Compliance Partners